Fri.May 10, 2024

article thumbnail

Farmers resist push for workers to wear protective gear against bird flu virus

STAT

WASHINGTON — The Centers for Disease Control and Prevention recommended this week that dairy and poultry farms with infected animals supply protective gear to workers in a bid to stave off human transmission of the H5N1 virus. The challenge now is making it happen. The CDC has no legal authority to order those protective measures, and health officials in some of the nine states with reported outbreaks in cattle have had little luck getting farmers to take them up on offers of free persona

364
364
article thumbnail

The Enhertu effect: Daiichi’s plan to build on the success of its crown jewel

PharmaVoice

The CEO of Daiichi Sankyo’s American business explains how the company plans to build off the momentum of its blockbuster cancer med.

130
130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Sanofi enters vaccine licensing deal with Novavax, giving beleaguered biotech a lifeline

STAT

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.   The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

Vaccines 364
article thumbnail

ASBM’s Michael Reilly: Preserve the US Interchangeable Standard that Has Helped Drive Physician and Patient Confidence in Biosimilars

Safe Biologics

In an April interview with EndpointsNews , an FDA official called on Congress to eliminate the distinction between biosimilars (which can be prescribed in place of their reference products by a physician) and “interchangeable” biosimilars, which can be substituted by pharmacists the way generics are. Doing so would undermine physician confidence in biosimilars and jeopardize treatment stability for many patients, according to ASBM’s Executive Director, Michael Reilly in a r esponse p

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Federal officials will fund farms’ protective measures to contain H5N1 bird flu

STAT

WASHINGTON — The federal government will provide livestock farms as much as $28,000 apiece to bolster protective measures and testing for the avian flu virus spreading among dairy cows, officials said Friday. The Agriculture Department also allotted $98 million to aid states restricting the interstate movement of affected cattle, and health officials announced they would put an additional $101 million toward expanded surveillance, tests, treatments, and vaccines for the virus, which has n

Vaccines 363
article thumbnail

What are the key immigration changes facing the pharma industry?

pharmaphorum

The pharma industry is facing major immigration policy changes that will impact hiring of skilled talent. This blog examines new visa and salary requirements for life sciences roles and their effect on the industry.

122
122

More Trending

article thumbnail

iTeos shares jump on TIGIT update; Acelyrin swaps CEOs

BioPharma Dive

Interim data surpassed expectations, iTeos said. Elsewhere, Acelyrin revealed chief executive officer Shao-Lee Lin is departing and Bluebird bio gave a fuller account of its gene therapy launches.

111
111
article thumbnail

STAT+: CRISPR edits fail to cure HIV patients in early test

STAT

BALTIMORE — An ambitious effort to cure HIV with CRISPR genome editing fell short in an early clinical trial, investigators announced Friday morning. In the study, run by Excision BioTherapeutics, researchers tried to use the gene editing tool to address a chief reason HIV has been so hard to cure. While antiviral drugs can clear patients of replicating virus, HIV is able to worm its way into a patients’ own DNA in certain cells.

360
360
article thumbnail

FDA delays decision on Moderna RSV vaccine

BioPharma Dive

The regulator cited “administrative constraints,” rather than any issue with Moderna’s trial data, for missing a May 12 deadline, the company said.

Vaccines 111
article thumbnail

Opinion: What nurses really want: sufficient staffing for patient care

STAT

Pizza. Coloring books. Goody bags. They could be activities at a 5-year-old’s birthday party. But they’re not: These are many employers’ attempts to lift the morale of nurses on the frontlines of chronically understaffed organizations. What nurses really want are better working conditions so they can deliver the best care possible to their patients.

360
360
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

Sanofi forges $1.2bn alliance with vaccines firm Novavax

pharmaphorum

Sanofi has licensed joint commercial rights to Novavax’s COVID-19 vaccine and will work with the biotech on the development of combined flu/COVID shots in a deal worth up to $1.2 billion.

Vaccines 115
article thumbnail

STAT+: Harvard scientists unveil the most detailed map of the brain ever: ‘It’s an alien world inside your own head’

STAT

About 10 years ago, a small piece of human brain arrived in the lab of Dr. Jeffrey Lichtman at Harvard. It came directly from an operating room of a nearby hospital, where it was excised from an epilepsy patient undergoing a procedure to reduce   her seizures. In the years that followed, Lichtman’s team methodically reconstructed the byzantine wiring patterns of the brain by feeding the 1-cubic-millimeter sample into a  $6 million device  that sliced it into impossibly-thin

Hospitals 319
article thumbnail

Challenges and opportunities in the CGT supply chain

European Pharmaceutical Review

the success of CGT depends on a robust and reliable supply chain” Cell and gene therapies (CGT) offer a revolutionary approach to the treatment, prevention and potential cure of diseases. These advanced medical treatments provide hope for patients suffering from conditions that have historically been poorly understood and widely considered incurable, including genetic diseases and cancers.

article thumbnail

Opinion: When heat threatens, use the wet bulb globe temperature to keep workers safe

STAT

A 30-year-old farm worker in North Carolina died last September on a day that was fairly typical for the state. Temperatures were in the mid-90s and the heat index , which includes humidity, was 96 degrees F. This index is often referred to as the “feels like” temperature, and is commonly used to gauge heat stress on the body. But use of the heat index to gauge whether José Arturo González Mendoza and his fellow sweet potato harvesters could work safety grossly underestim

286
286
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

ARRS funding can be used to fund DPPs

The Pharmacist

The Additional Roles Reimbursement Scheme (ARRS) could be used to fund pharmacists to spend time as designated prescribing practitioners (DPPs), NHS England has announced. Speaking at the Clinical Pharmacy Congress in London today, Rebecca Burgoyne, chief pharmaceutical officer’s clinical fellow, announced a ‘new opportunity’ to use ARRS funding for pharmacy training roles.

98
article thumbnail

The public wants Medicare to cover obesity drugs

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hi all. Today we’re talking about improving the global reach of gene therapies, and about why offering access to ancestral populations could be so powerful. We see in a KFF survey that a majority of Americans want obesity drugs to be covered by Medicare, offer up a cool new podcast, and more.

article thumbnail

Automation Studio CoPilot: Your AI companion for B&R software

Express Pharma

In today’s industrial landscape, the software is getting more and more powerful to help machine developers. The newly released Automation studio 6 introduces CoPilot which helps with creation of machine software in languages like Structure Text, C and C++. At the click of a button engineers can leverage the power of generative AI to generate and optimize code.

104
104
article thumbnail

STAT+: After its last deal fell through, Maze Therapeutics finds new partner for rare disease drug

STAT

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.   Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

311
311
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

London’s life sciences scene upbeat as 2024 conference season begins

pharmaphorum

London's burgeoning life sciences scene is kicking off 2024 with optimism as the city prepares to host major conferences like Anglonordic. Discover how antibody discovery biotechs like Alchemab are driving growth and innovation in the sector.

117
117
article thumbnail

STAT+: Up and down the ladder: The latest comings and goings

STAT

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.  That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.

251
251
article thumbnail

Shionogi and Maze seal worldwide exclusive in bid to cure Pompe disease

Outsourcing Pharma

In an interesting development in the field of rare disease therapeutics, Shionogi & Co., Ltd., and Maze Therapeutics, Inc. have sealed an exclusive worldwide license agreement for MZE001, a novel therapeutic candidate aimed at tackling Pompe disease.

94
article thumbnail

STAT+: Pharmalittle: We’re reading about Sanofi licensing Novavax’s Covid shot, Moderna’s RSV vaccine, and more

STAT

Hello there and happy Friday from STAT’s London outpost, where the weekend is mere hours away. STAT reporter Andrew Joseph here, filling in for Mr. Pharmalot for the day. Spring has fully sprung here in the U.K., and our weekend plans include plenty of park time, and if we’re being honest, likely some time at the pub as well. Wishing you all sunny days ahead, and a reminder to ourselves and to all to bring the sunscreen.

Vaccines 251
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Reuters Pharma Europe 2024 – Peter Stenico

pharmaphorum

An insightful interview with Peter Stenico, global head of biosimilars and country president, Sandoz Austria at Reuters Pharma Europe, Barcelona 2024

article thumbnail

Global healthcare partners and Indian pharma companies: Making medicines affordable

Express Pharma

In the expansive landscape of global healthcare, India has emerged as a pivotal player, shaping the accessibility and affordability of essential medicines worldwide. As the world’s leading supplier of generic drugs, India’s pharmaceutical industry has become a ray of hope for millions as it ensures quality-assured and cost-effective treatments reach those who need them the most.

Vaccines 102
article thumbnail

WestGene wins FDA approval for mRNA vaccine to treat certain cancers

Pharmaceutical Technology

The FDA approved WestGene’s mRNA therapeutic cancer vaccine as mRNA cancer vaccine development rises in popularity.

Vaccines 111
article thumbnail

Maze gets new Pompe partner after FTC blocks Sanofi deal

pharmaphorum

Five months after Sanofi walked away from a deal with Maze Therapeutics on an oral Pompe disease therapy, Shionogi has snapped up the drug.

114
114
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Shionogi secures licence for Maze’s Pompe disease treatment

Pharmaceutical Technology

Shionogi has concluded an exclusive global licence agreement for Maze Therapeutics’ MZE001 aimed at treating Pompe disease.

105
105
article thumbnail

Deputy CPhO: NHSE could consider employing trainee pharmacists

The Pharmacist

NHS England (NHSE) could consider employing pre-registration pharmacists, the deputy chief pharmaceutical officer (CPhO) for England has suggested. At the Clinical Pharmacy Congress (CPC) today, Richard Cattell said he was thinking about ways to bring the pharmacist profession – across community, practice and hospital settings – together to address workforce and training challenges.

article thumbnail

NHS reduces long waits for cancer care and achieves faster ambulance responses

Pharma Times

For the second month in a row, the NHS has met the 28-day faster diagnosis target for cancer

112
112
article thumbnail

Shinogi and Maze seal worldwide exclusive in bid to cure Pompe disease

Outsourcing Pharma

In an interesting development in the field of rare disease therapeutics, Shionogi & Co., Ltd., and Maze Therapeutics, Inc. have sealed an exclusive worldwide license agreement for MZE001, a novel therapeutic candidate aimed at tackling Pompe disease.

84
article thumbnail

Novavax gets a lifeline with Sanofi vaccine pact

BioPharma Dive

Sanofi will ally with the under-pressure biotech, paying $500 million upfront for rights to co-commercialize Novavax’s COVID shot and develop combination influenza vaccines.